Aldeyra Therapeutics Statistics
Total Valuation
ALDX has a market cap or net worth of $41.56 million. The enterprise value is $1.05 million.
| Market Cap | 41.56M |
| Enterprise Value | 1.05M |
Important Dates
The next estimated earnings date is Friday, November 20, 2026, after market close.
| Earnings Date | Nov 20, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
ALDX has 60.33 million shares outstanding. The number of shares has increased by 0.63% in one year.
| Current Share Class | 60.33M |
| Shares Outstanding | 60.33M |
| Shares Change (YoY) | +0.63% |
| Shares Change (QoQ) | +0.05% |
| Owned by Insiders (%) | 3.60% |
| Owned by Institutions (%) | 50.36% |
| Float | 48.95M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.09 |
| P/TBV Ratio | 1.09 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.45, with a Debt / Equity ratio of 0.01.
| Current Ratio | 5.45 |
| Quick Ratio | 5.20 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -21.39 |
Financial Efficiency
Return on equity (ROE) is -45.29% and return on invested capital (ROIC) is -25.13%.
| Return on Equity (ROE) | -45.29% |
| Return on Assets (ROA) | -20.84% |
| Return on Invested Capital (ROIC) | -25.13% |
| Return on Capital Employed (ROCE) | -56.90% |
| Weighted Average Cost of Capital (WACC) | 13.12% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$3.19M |
| Employee Count | 6 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -87.15% in the last 52 weeks. The beta is 1.29, so ALDX's price volatility has been higher than the market average.
| Beta (5Y) | 1.29 |
| 52-Week Price Change | -87.15% |
| 50-Day Moving Average | 1.05 |
| 200-Day Moving Average | 2.17 |
| Relative Strength Index (RSI) | 35.24 |
| Average Volume (20 Days) | 995,897 |
Short Selling Information
The latest short interest is 3.19 million, so 5.28% of the outstanding shares have been sold short.
| Short Interest | 3.19M |
| Short Previous Month | 3.47M |
| Short % of Shares Out | 5.28% |
| Short % of Float | 6.51% |
| Short Ratio (days to cover) | 1.78 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -20.20M |
| Pretax Income | -19.13M |
| Net Income | -19.13M |
| EBITDA | -19.84M |
| EBIT | -20.20M |
| Earnings Per Share (EPS) | -$0.32 |
Balance Sheet
The company has $40.97 million in cash and $458,698 in debt, with a net cash position of $40.52 million or $0.67 per share.
| Cash & Cash Equivalents | 40.97M |
| Total Debt | 458,698 |
| Net Cash | 40.52M |
| Net Cash Per Share | $0.67 |
| Equity (Book Value) | 35.22M |
| Book Value Per Share | 0.58 |
| Working Capital | 35.04M |
Cash Flow
In the last 12 months, operating cash flow was -$19.12 million and capital expenditures -$23,097, giving a free cash flow of -$19.15 million.
| Operating Cash Flow | -19.12M |
| Capital Expenditures | -23,097 |
| Depreciation & Amortization | 357,133 |
| Net Borrowing | -15.30M |
| Free Cash Flow | -19.15M |
| FCF Per Share | -$0.32 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
ALDX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -0.63% |
| Shareholder Yield | -0.63% |
| Earnings Yield | -46.05% |
| FCF Yield | -50.08% |
Analyst Forecast
The average price target for ALDX is $6.60, which is 857.91% higher than the current price. The consensus rating is "Buy".
| Price Target | $6.60 |
| Price Target Difference | 857.91% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |